EFFICACY OF 5-AZACITIDINE IN THE TREATMENT OF HIGHER-RISK MYELODISPLASTIC SYNDROMES, ACUTE MYELOID LEUKEMIA AND CHRONIC MYELOMONOCYTIC LEUKEMIA: EXPERIENCE AT A SINGLE CENTER

被引：0
|
作者：
Vazquez, H. Hernandez [1 ]
Diez, E. Amutio [1 ]
Eizaguirre, I. Olazabal [1 ]
Malcorra, A. Balerdi [1 ]
Urkixo, I. Etxeguren [1 ]
Iruin, A. Uresandi [1 ]
Pomposo, M. Puente [1 ]
Usategui, M. Duenas [1 ]
Mazon, J. Mateos [1 ]
Perez, A. Iglesias [1 ]
Quintana, A. Moreto [1 ]
Frances, M. A. Pinan [1 ]
Goni, F. Floristan [1 ]
Martinez, M. C. Alvarez [1 ]
Ontoria, I. Hernandez [1 ]
Garcia-Ruiz, J. C. [1 ]
机构：
[1] Hosp Cruces, Baracaldo, Spain
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2010年 / 95卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1405
引用
收藏
页码：564 / 565
页数：2
相关论文
共 50 条
  • [31] Low Efficacy and High Mortality Associated with Clofarabine Treatment of Patients with Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes
    Roberts, Daniel A.
    Wadleigh, Martha
    McDonnell, Anne
    DeAngelo, Daniel J.
    Stone, Richard M.
    Steensma, David P.
    BLOOD, 2014, 124 (21)
  • [32] Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence.
    Zeidan, Amer Methqal
    Schuster, Michael
    Joris, Magalie
    Krauter, Jurgen
    Maertens, Johan
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ma, Wendy
    Zeremski, Mirjana
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [33] Health-related quality of life (HRQoL) in patients with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and chronic myelomonocytic leukemia (CMML) receiving glasdegib plus azacitidine (AZA).
    Wang, Eunice S.
    Bell, Timothy
    Zeidan, Amer Methqal
    Bhattacharyya, Helen
    Kudla, Art
    Chan, Geoffrey
    Sekeres, Mikkael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [34] Predictive Model for Infection Risk in Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Patients Treated With Azacitidine; Azacitidine Infection Risk Model: The Polish Adult Leukemia Group Study
    Madry, Krzysztof
    Lis, Karol
    Biecek, Przemyslaw
    Mlynarczyk, Magda
    Rytel, Agoda
    Gorka, Michal
    KacFrzyk, Piotr
    Dutka, Magdalena
    Rodzaj, Marek
    Bolkun, Lukasz
    Krochmalczyk, Dorota
    Latka, Ewa
    Drozd-Sokolowska, Joanna
    Waszczuk-Gajda, Anna
    Knopinska-Posluszny, Wanda
    Kopinska, Anna
    Subocz, Edyta
    Masternak, Anna
    Guzicka-Kazimierczak, Renata
    Gil, Lidia
    Machowicz, Rafal
    Bilinski, Jaroslaw
    Giebe, Sebastian
    Czerw, Tomasz
    Dwilewicz-Trojaczek, Jadwiga
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 264 - +
  • [35] Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine
    Stefania Infante, Maria
    Munoz, Carolina
    Heras, Cecilia
    Angeles Foncillas, Maria
    Gonzalez, Isabel
    Lucea, Irene
    Echavarria, Eva
    Aramendi, Teresa
    Angel Hernandez, Jose
    EUROPEAN JOURNAL OF DERMATOLOGY, 2015, 25 (06) : 622 - 623
  • [36] Leukemia cutis in myelodysplastic syndrome and chronic myelomonocytic leukemia patients treated with adjusted dose 5-azacitidine
    María Stefania Infante
    Carolina Muñoz
    Cecilia Heras
    María Angeles Foncillas
    Isabel González
    Irene Lucea
    Eva Echavarria
    Teresa Aramendi
    José Angel Hernández
    European Journal of Dermatology, 2015, 25 : 622 - 623
  • [37] Efficacy of hypomethylating agents administration before allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia, myelodisplastic syndrome, juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
    Bondarenko, S.
    Ovechkina, V.
    Morozova, E.
    Osipova, A.
    Smirnova, A.
    Samorodova, I.
    Gindina, T.
    Barhatov, I.
    Alyanskiy, A.
    Kulagin, A.
    Moiseev, I.
    Zubarovskaya, L.
    Afanasyev, B.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S485 - S485
  • [38] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    U Platzbecker
    F Braulke
    A Kündgen
    K Götze
    G Bug
    C Schönefeldt
    K Shirneshan
    C Röllig
    M Bornhäuser
    R Naumann
    J Neesen
    A Giagounidis
    W-K Hofmann
    G Ehninger
    U Germing
    D Haase
    M Wermke
    Leukemia, 2013, 27 : 1403 - 1407
  • [39] Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
    Platzbecker, U.
    Braulke, F.
    Kuendgen, A.
    Goetze, K.
    Bug, G.
    Schoenefeldt, C.
    Shirneshan, K.
    Roellig, C.
    Bornhaeuser, M.
    Naumann, R.
    Neesen, J.
    Giagounidis, A.
    Hofmann, W-K
    Ehninger, G.
    Germing, U.
    Haase, D.
    Wermke, M.
    LEUKEMIA, 2013, 27 (06) : 1403 - 1407
  • [40] Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).
    Zhou, Xiaofei
    Mould, Diane R.
    Zhao, Dan
    Sekeres, Mikkael A.
    Ades, Lionel
    Swords, Ronan T.
    Handa, Hiroshi
    Fram, Robert J.
    Faller, Douglas V.
    Tsukurov, Olga
    Gupta, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345